In summary, the present meta-analysis indicates that CD133 expression is associated with a poor OS and a high rate of lymph node metastasis and no correlation exists between CD133 expression and DFS or other common clinicopathological parameters such as histology and tumor differentiation. The gene discussed is PROM1; the disease is metastatic malignant neoplasm in the lymph nodes.